Urinary incontinence: Economic burden and new choices in pharmaceutical treatment

Advances in Therapy

Volumn 23, Issue 4, 2006, Pages 556-573

  Levy, Richard ^a   Muller, Nancy ^b  

^a National Pharmaceutical Council   (United States)

^b National Association for Continence   (United States)

Author keywords

Economic burden; Pharmaceutical treatment; Urinary incontinence

Indexed keywords

DARIFENACIN; DETROL LA; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BEHAVIOR THERAPY; BLURRED VISION; CONSTIPATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG DOSAGE FORM; DRUG WITHDRAWAL; DRY EYE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEART PALPITATION; HEAT INTOLERANCE; HUMAN; INDWELLING CATHETER; LONG TERM CARE; MEDICAID; MEDICARE; MOLECULAR MODEL; NURSING HOME; OVERACTIVE BLADDER; PATIENT COMPLIANCE; REVIEW; STRESS INCONTINENCE; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; UNITED STATES; URGE INCONTINENCE; URINE INCONTINENCE; XEROSTOMIA;

ADULT; AGED; AGING; DOSAGE FORMS; FEMALE; HOMES FOR THE AGED; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NURSING HOMES; PARASYMPATHOLYTICS; SEX FACTORS; URINARY INCONTINENCE;

EID: 33750969361     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850045     Document Type: Review

References (62)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002;187:116-126.
2. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26:367-374.
3. Optimizing quality of care and cost effectiveness in the treatment of overactive bladder. Am J Manag Care. 2001;7(2 suppl):S43-S45.
4. Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity: a review of the evidence regarding the long-term outcome of the overactive bladder. J Urol. 2003; 169:843-848.
5. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63:461-465.
6. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-336.
7. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc. 1998; 46:473-480.
8. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynaecol Obstet. 2003;82:327-338.
9. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000; 6(11 suppl):S565-S573.
10. Garraway WM, Russell EB, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract. 1993;43:318-321.
11. Burgio KL, Ives DG, Locher JL, Arena VC, Kuller LH. Treatment seeking for urinary incontinence in older adults. J Am Geriatr Soc. 1994;42:208-212.
12. Branch LG, Walker LA, Wetle TT, DuBeau CE, Resnick NM. Urinary incontinence knowledge among community-dwelling people 65 years of age and older. J Am Geriatr Soc. 1994;42:1257-1262.
13. Penning-van Beest FJ, Sturkenboom MC, Bemelmans BL, Herings RM. Undertreatment of urinary incontinence in general practice. Ann Pharmacother. 2005;39:17-21.
14. Palmer MH, McCormick KA, Langford A, Langlois J, Alvaran M. Continence outcomes: documentation on medical records in the nursing home environment. J Nurs Care Qual. 1992; 6:36-43.
15. DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients' perspective and explanatory style. J Am Geriatr Soc. 1998;46:683-692.
16. Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics. 1996;9:11-23.
17. Grimby A, Milsom I, Molander U, Wiklund I, Ekelund P. The influence of urinary incontinence on the quality of life of elderly women. Age Ageing. 1993;22:82-89.
18. Noelker LS. Incontinence in elderly cared for by family. Gerontologist. 1987;27:194-200.
19. Goode PS. Predictors of treatment response to behavioral therapy and pharmacotherapy for urinary incontinence. Gastroenterology. 2004;126(1 suppl 1):S141-S145.
20. Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med. 2002;69:761,765-766,768-769.
21. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology. 1998;51:355-361.
22. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 suppl):S574-S579.
23. Muller N. What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research. Urol Nurs. 2005;25:109-115.
24. Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98:398-406.
25. Martin CM. Urinary incontinence in the elderly. Consult Pharm. Available at: http://www.ascp.com/publications/tcp/1997/aug/elderly.html. Accessed September 7, 2006.
26. Nuotio M, Tammela TL, Luukkaala T, Jylha M. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence. J Gerontol A Biol Sci Med Sci. 2003;58:756-762.
27. Nygaard I, Thom DH, Calhoun EA. Urinary incontinence in women. In: Nygaard I, Thom DH, Calhoun EA, Litwin MS, Saigal CS, eds. Urologic Diseases in America. Washington, DC: US Government Publishing Office; 2004.
28. Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. Value Health. 2006;9:272-274.
29. Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P. Cost of stress urinary incontinence: a claims data analysis. Pharmacoeconomics. 2004;22:95-105.
30. Chartbook on Trends in the Health of Americans. United States, 2002. Hyattsville, Md: National Center for Health Statistics; 2002.
31. Watson NM, Brink CA, Zimmer JG, Mayer RD. Use of the Agency for Health Care Policy and Research urinary incontinence guideline in nursing homes. J Am Geriatr Soc. 2003;51:1779-1786.
32. Turnbull GB. CMS new guidance to LTC surveyors effective June 27: F315-urinary incontinence and catheters. Ostomy Wound Manage. 2005;51:18-19.
33. Wound ostomy and continence nurses. Position statement on coverage for pelvic floor biofeedback therapy. Available at: http://www.wocn.org/ publications/posstate/biofeedback.html. Accessed September 7, 2006.
34. Baker DI, Bice TW The influence of urinary incontinence on publicly financed home care services to low-income elderly people. Gerontologist. 1995;35:360-369.
35. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of osteoporotic fractures research group. J Am Geriatr Soc. 2000;48:721-725.
36. McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care. 2001;7(2 suppl):S62-S75.
37. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health. 2005;8:495-505.
38. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005;48:5-26.
39. Franks M, Chartier-Kastler E, Chancellor MB. New pharmacologic and minimally invasive therapies for the overactive bladder. Drug Benefit Trends. 2000;12:49-57.
40. Chapple CR, Martinez-Garcia R, Selvaggia L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464-470.
41. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687-695.
42. Staskin DR. Transdermal systems for overactive bladder: principles and practice. Rev Urol. 2003;5(suppl 8):S26-S30.
43. Zhou Z, Barr C, Torigoe Y, et al. Persistence of therapy with drugs for overactive bladder (abstract). Value Health. 2001;4:161.
44. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000;20:470-475.
45. Chui MA, Williamson T, Arciniego J, et al. Patient persistency with medications for overactive bladder (abstract). Value Health. 2004;7:366.
46. Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface. 2004;17:54-60.
47. Andersson KE. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl. 2002; 1:23-28.
48. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46-53.
49. Parsons M, Robinson D, Cardozo L. Darifenacin in the treatment of overactive bladder. Int J Clin Pract. 2005;59:831-838.
50. Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol. 1996;41:73-75.
51. Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf. 2004;27:1043-1057.
52. Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol. 2005; 48:102-109.
53. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs. 2004;64:2433-2446.
54. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41:636-644.
55. Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment Curr Urol Rep. 2005;6:410-418.
56. Bolge SC, Cerulli A, Kahler KH, Gause D. Impact of successful treatment of overactive bladder on health care resource use and productivity. Drug Benefit Trends. 2006;18:244-255.
57. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics. 2004;22:1047-1059.
58. Bentkover JD, Chapple C, Corey R, Hill S, Stewart EJ. Adapting a US cost-offset economic model for overactive bladder for the European marketplace (abstract). Value Health. 2000;3:361.
59. Engqvist H. A new voice for silent sufferers. Scrip. 2005;146:35-37.
60. Hegde SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Investig Drugs. 2004;5:40-49.
61. Wertheimer AI, Santella TM, Finestone AJ, Levy RA. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther. 2005;22:559-577.
62. Wertheimer AI, Levy R, O'Connor TW. Too many drugs? The clinical and economic value of incremental innovations. In: Farquhar I, Summers K, Sorkin A, eds. Investing in Health: the Social and Economic Benefits of Health Care Innovation. Greenwich, Conn: JAI Press; 2001;14:77-88.